Chemical Property of CID 657387
Chemical Property:
- Appearance/Colour:White solid
- Vapor Pressure:1.27E-11mmHg at 25°C
- Melting Point:165-167 °C
- Boiling Point:519.6 °C at 760 mmHg
- Flash Point:268 °C
- PSA：58.56000
- LogP:4.43430
- Storage Temp.:2-8°C
- Solubility.:Slightly soluble in cold water, soluble in methanol and in hot water, practically insoluble in ethanol (96 per cent).
- Hydrogen Bond Donor Count:3
- Hydrogen Bond Acceptor Count:5
- Rotatable Bond Count:11
- Exact Mass:377.1757714
- Heavy Atom Count:26
- Complexity:368
- Purity/Quality:
-
99% *data from raw suppliers
Propafenone hydrochloride
*data from reagent suppliers
Safty Information:
- Pictogram(s):
T, 
Xn
- Hazard Codes:T,Xn
- Statements:
46-22
- Safety Statements:
53-36/37/39-45
- MSDS Files:
-
SDS file from LookChem
Total 1 MSDS from other Authors
Useful:
- Canonical SMILES:[H+].CCCNCC(COC1=CC=CC=C1C(=O)CCC2=CC=CC=C2)O.[Cl-]
-
Description
Propafenone hydrochloride is a class I anti-arrhythmic agent with basic local anaesthetic and membrane-stabilizing properties. Some P-adrenergic blocking action has also been described. Propafenone decreases the depolarization velocity and slows conduction in the His-Purkinje system with resultant increase in the PR interval and the QRS complex. Propafenone is used in the treatment of paroxysmal supraventricular tachycardias and ventricular arrhythmias.Propafenone should not be used in uncontrolled cardiac failure, severe obstructive pulmonary disease or marked hypotension. Propafenone may worsen myasthenia gravis.
-
Uses
Propafenone hydrochloride is a class IC antiarrhythmic agent used for the management of severe ventricular and supraventricular arrhythmias. It has beta-blocking and weak calcium channel blocking properties, as well as some negative inotropic activity. Propafenone is in a class of medications called antiarrhythmics. It works by acting on the heart muscle to improve the heart's rhythm. Sodium channel blocker. Antiarrhythmic (class IC)
-
Clinical Use
Anti-arrhythmic agent:
Ventricular arrhythmias
Paroxysmal supraventricular tachyarrhythmias,
(including paroxysmal atrial flutter or fibrillation,
and paroxysmal re-entrant tachycardias involving
the AV node or accessory pathway) where standard
therapy has failed or is unsuitable
-
Drug interactions
Potentially hazardous interactions with other drugs
Anti-arrhythmics: increased myocardial depression
with other anti-arrhythmics.
Antibacterials: increased metabolism with rifampicin
(reduced effect).
Anticoagulants: enhanced anticoagulant effect of
coumarins.
Antidepressants: increased risk of arrhythmias
with tricyclics; metabolism of propafenone possibly
inhibited by paroxetine (increased risk of toxicity).
Antihistamines: increased risk of ventricular
arrhythmias with mizolastine - avoid.
Antipsychotics: increased risk of ventricular
arrhythmias with antipsychotics that prolong the QT
interval.
Antivirals: concentration of propafenone increased
by saquinavir and ritonavir and possibly by
fosamprenavir, increased risk of ventricular
arrhythmias - avoid; use with caution with
telaprevir.
Beta-blockers: increased myocardial depression;
increased concentration of metoprolol and
propranolol.
Cardiac glycosides: increased digoxin concentration -
halve digoxin dose.
Ciclosporin: possibly increased ciclosporin
concentration.
Ulcer-healing drugs: levels increased by cimetidine.
